Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.07M | 27.41M | 27.94M | 43.50M | 19.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.07M | 27.41M | 27.94M | 43.50M | 19.95M |
| Cost of Revenue | 2.47M | 6.04M | 9.29M | 12.04M | 11.21M |
| Gross Profit | 23.61M | 21.37M | 18.65M | 31.47M | 8.74M |
| SG&A Expenses | 25.39M | 27.29M | 29.17M | 28.12M | 26.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.96M | 92.15M | 93.07M | 85.98M | 75.39M |
| Operating Income | -62.88M | -64.73M | -65.12M | -42.48M | -55.44M |
| Income Before Tax | -57.49M | -72.03M | -64.21M | -37.75M | -65.34M |
| Income Tax Expenses | 9.01M | 9.06M | 9.28M | 9.52M | 9.74M |
| Earnings from Continuing Operations | -66.50 | -81.09 | -73.49 | -47.27 | -75.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.50M | -81.09M | -73.49M | -47.27M | -75.08M |
| EBIT | -62.88M | -64.73M | -65.12M | -42.48M | -55.44M |
| EBITDA | -62.29M | -64.15M | -64.53M | -41.88M | -54.85M |
| EPS Basic | -4.24 | -5.14 | -4.67 | -3.02 | -5.02 |
| Normalized Basic EPS | -0.75 | -0.93 | -0.85 | -0.50 | -0.89 |
| EPS Diluted | -4.24 | -5.14 | -4.67 | -3.02 | -5.02 |
| Normalized Diluted EPS | -0.75 | -0.93 | -0.85 | -0.50 | -0.89 |
| Average Basic Shares Outstanding | 188.26M | 189.08M | 188.58M | 185.32M | 177.01M |
| Average Diluted Shares Outstanding | 62.75M | 63.03M | 62.86M | 61.77M | 59.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |